專業人才 > 免疫

張文震, M.D.
單位: 林口長庚紀念醫院
現職: 腫瘤科副教授級主治醫師
聯絡地址: 桃園市龜山區復興街五號
電話: 03-328-1200 分機:8825
E-mail: wen1902@hotmail.com

研究領域:
  • Oncology 腫瘤
  • Immunology 免疫學
  • Targeted therapy 標靶治療
  • Gene signature
研究成果
I am especially interested in the diagnosis, treatment and experimental therapy in lung cancer, kidney cancer and skin cancer. My primary area of clinical research is joining global trials to develop novel therapeutic agents, including bevacizumab, sorafenib, sunitinib, axitinib, pazopanib, temsirolimus, everolimus, lapatinib, gefitinib, erlotinib and tasisulam to fight against kidney cancer, lung cancer and malignant melanoma. Currently he is actively involved in the consensus consultation and multi-disciplinary care of the kidney cancer patients, including the staging procedures, management and systemic cytokine and targeted therapies in Taiwan. I am also experienced in translational research, studying specific markers to predict the treatment outcome and safety of patients using targeted therapy. Our team have noticed a high incidence of skin toxicity in Taiwan and published the clinicopathological characteristics of the hand foot-skin reaction in kidney cancer patients receiving multi-kinase inhibitors. Besides kidney cancer, we also published the first paper disclosing a high incidence rate of EGFR mutation in Asian patients with lung adenocarcinoma, which was extremely sensitive to EGFR tyrosine kinase inhibitors. Thus far, we have published more than 100 original articles, scientific reviews and abstracts. Now, I am in charge for the safety and quality-of-care for patients undergoing systemic anticancer therapy in Chang Gung Memorial Hospital to offer every patient the best chance of cure and the least toxicity.

工作經歷:

1989-1992 > Resident in Department of Internal Medicine, Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan
1992-1994 > Clinical Fellow in Division of Medical Oncology, Department of Internal Medicine, CGMH
1994-1995 > Clinical Fellow in Division of Hematology, Department of Internal Medicine, CGMH
1995-1997 > Attending Physician in Medical Oncology, CGMH
1997-1999 > Research Fellow in Department of Surgery, Mount Zion Cancer Center, University of California, San Francisco
1999-present  > Attending Physician in Medical Oncology, CGMH
2009-present  > Associate Professor
學歷:
1982 - 1989 MD, Chung Shan Medical University, Tai-Chung, Taiwan

代表論文:
1. Kun-Yun Yeh, Hung-Ming Wang, John Wen-Cheng Chang, Jen-Seng Huang, Chien-Hong Lai, Yii-Jenq Lan, Tsung-Han Wu, Pei-Hung Chang, Hang Wang, Chang-Jer Wu, Simon Hsia, and Cheng-Hsu Wang. Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013, 116(1): 41-48.
2. Chiao-En Wu, Chia-Hsun Hsieh, Cheng-Jen Chang, Jiun-Ting Yeh, Tseng-tong Kuo, Chih-Hsun Yang, Yung-Feng Lo, Kun-Ju Lin, Yung-Chang Lin, John Wen-Cheng Chang*. Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy. J Formos Med Assoc. 2013, Aug 19. DOI: 10.1016/j.jfma.2013.06.018.
3. John Wen-Cheng Chang, Nien-Chih Wei, Hung-Ju Su, Jie-Len Huang, Tse-Ching Chen, Yi-Cheng Wu, Chih-Teng Yu, Ming-Mo Hou, Chia-Hsun Hsieh, Jia-Juan Hsieh, Chiao-En Wu, Hsin-Yi Cheng, Todd Hsu and Tzu-Hao Wang. Comparison of Genomic Signatures of Non-small Cell Lung Cancer Recurrence between Two Microarray Platforms. Anticancer Research. 2012, 32(4): 1259-1265.
4. John Wen-Cheng Chang, Sumitra Thongprasert, Elaine Wright, Kenneth Tsang, Heung-Tae Kim, Myung-Ju Ahn, Joo-Hang Kim, Jin Hyoung Kang, Sang-We Kim, Stefan Walzer. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia Pac J Clin Oncol. 2011, 7(suppl 2): 13-21.
5. Ying-Ying Li, John Wen-Cheng Chang, Ling-Ling Hsieh, Kun-Yun Yeh. Neutralization of interleukin (IL)-10 released by monocytes/macrophages enhances the up-regulatory effect of monocyte/macrophage-derived IL-6 on expressions of IL-6 and MUC1, and migration in HT-29 colon cancer cells. Cell Immunology. 2010, 265(2): 164-171.

所有論文著作一覽表